VCAM1 and myeloid sarcoma: Subsequent studies confirmed these and identified 29 additional risk variants, focusing on genes involved in lymphocyte function, Vitamin D metabolism (CYP27B1 and CYP24A1), and targets of MS immune-modulatory therapies (VCAM1 and IL2RA) (12).